HIGHTIDE (2511) presents kidney benefit data for HTD1801 at the American Society of Nephrology Annual Meeting
I'm PortAI, I can summarize articles.
HIGHTIDE showcased the renal benefit data of HTD1801 in patients with mild renal impairment at the 58th Annual Meeting of the American Society of Nephrology. Clinical results indicate that HTD1801 has the potential to improve eGFR changes in chronic kidney disease (CKD) patients and restore kidney function, bringing substantial health benefits to patients. HTD1801 is a globally innovative new molecular entity focused on cardiorenal metabolic system diseases (CKM)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: etnet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments